PHARMADIGM INC has a total of 12 patent applications. Its first patent ever was published in 1995. It filed its patents most often in Australia, WIPO (World Intellectual Property Organization) and Canada. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are SHANGHAI INST OF LIFE SCIENCES, VACTECH OY and BIONTECH RNA PHARMACEUTICALS GMBH.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 5 | |
#2 | WIPO (World Intellectual Property Organization) | 5 | |
#3 | Canada | 1 | |
#4 | United States | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Microorganisms | |
#4 | Peptides | |
#5 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Araneo Barbara A | 12 |
#2 | Dowell Tad | 4 |
#3 | Norton Steven D | 4 |
#4 | Ricigliano Joseph W | 3 |
#5 | Gebhard John | 2 |
#6 | Lockerbie R Owen | 2 |
#7 | Mckay Lawrence | 2 |
#8 | Orlinska Urszula | 1 |
#9 | Daynes Raymond A | 1 |
#10 | Farrukh Imad S | 1 |
Publication | Filing date | Title |
---|---|---|
WO0025820A1 | Compounds and methods for genetic immunization | |
AU3467699A | Method for reducing central nervous system impairment | |
AU3083299A | Screening for dhea mimetics using members of the inflammatory cell signalling cascade specifically modulated by dhea as targets | |
US5795872A | DNA construct for immunization |